Abstract: A method has been developed to produce stable cell-matrix microspheres with up to 100% encapsulation efficiency and high cell viability, using matrix or biomaterial systems with poor shape and mechanical stability for applications including cell therapeutics via microinjection or surgical implantation, 3D culture for in vitro expansion without repeated cell splitting using enzymatic digestion or mechanical dissociation and for enhanced production of therapeutic biomolecules, and in vitro modeling for morphogenesis studies. The modified droplet generation method is simple and scalable and enables the production of cell-matrix microspheres when the matrix or biomaterial system used has low concentration, with slow phase transition, with poor shape and mechanical stability.

Abstract: Compositions that include nanoscale structured materials or precursors thereof (e.g., self-assembling peptides) are described. The compositions can include other substances (e.g., a vasoconstrictor). Also described are methods for using the compositions to promote hemostasis, to protect the skin or wounds from contamination, to decontaminate a site upon removal of previously applied compositions that provided a protective coating, and to inhibit the movement of bodily substances other than blood. The compositions are also useful in isolating tissue, removing tissue, preserving tissue (for, e.g., subsequent transplantation or reattachment), and as bulking, stabilizing or hydrating agents. Medical devices that include the compositions (e.g., a stent or catheter), bandages or other wound dressings, sutures, and kits that include the compositions are also described.

Abstract: Compositions that include nanoscale structured materials or precursors thereof (e.g., self-assembling peptides) are described. The compositions can include other substances (e.g., a vasoconstrictor). Also described are methods for using the compositions to promote hemostasis, to protect the skin or wounds from contamination, to decontaminate a site upon removal of previously applied compositions that provided a protective coating, and to inhibit the movement of bodily substances other than blood. The compositions are also useful in isolating tissue, removing tissue, preserving tissue (for, e.g., subsequent transplantation or reattachment), and as bulking, stabilizing or hydrating agents. Medical devices that include the compositions (e.g., a stent or catheter), bandages or other wound dressings, sutures, and kits that include the compositions are also described.

Abstract: The current invention relates to novel platinum(II) based organometallic materials. These materials show high emission quantum efficiencies and low self-quenching constant. Also provided are high efficiency, green to orange emitting organic light-emitting diode (OLED) that are fabricated using platinum(II) based organometallic materials as the light-emitting material. The organometallic materials of the invention are soluble in common solvents; therefore, solution process methods such as spin coating and printing can be used for device fabrication. The devices fabricated from these materials show low efficiency roll-off.

Abstract: Water-soluble derivatives and/or prodrugs of acacetin are described herein. The compounds can be used as cardioprotection agents against myocardial infarction induced by ischemia-reperfusion. In one embodiment the compounds are used to treat ischemic cardiac diseases. In the preferred embodiment, the compounds are used to treat and/or prevent myocardial infarction in humans.

Abstract: An optical transmission system comprises at least one first connection point and one second connection point arranged to transmit and receive at least one channel signal transmitted via at least one optical means connecting the first connection point and the second connection, wherein each of the at least one channel signal is reversibly configurable to be transmitted in either a first direction or a second direction between the first connection point and the second connection point. A method of transmitting at least one channel signal between a first connection point and a second connection point via at least one optical media in an optical transmission system, wherein each of the at least one channel signal is reversibly configurable to be transmitted in either a first direction or a second direction between the first and the second connection points.

Abstract: Transgenic plants having increased growth rate and increase yield are disclosed, and methods for making the same. In one embodiment, the method comprises: transforming a plant or plant cell with a nucleic acid molecule comprising a plant kinase and/or phosphatase gene selected from NG6, NG21, NG24, NG28, and NG32, and over-expressing said kinase and/or phosphatase gene in the plant or plant cell.

Abstract: The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity.

Abstract: Compounds which exhibit antiviral activity, particularly against influenza virus, and methods of making and using thereof are described herein. In one embodiment, the compounds are heterocyclic amides containing piperazine and isozazole rings and optionally substituted with one or more substituents. The compounds can be formulated with one or more pharmaceutically acceptable excipients to form compositions suitable for enteral or parenteral administration. The compounds are preferably used to treat or prevent Influenza A infections, such as H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, and H10N7.

Abstract: Compositions which self-assemble under physiological conditions are formulated for application to wounds. The formulations include a pharmaceutically acceptable carrier or are provided as part of a medical device or coating. The formulations may also include other therapeutic, prophylactic or diagnostic agents. The formulation can be administered as appropriate for treatment of one or more disorders or conditions. For example, the formulation may be applied to repair an injury or during surgery of the lung, eye or dura, or following an epidural or spinal tap, to stop leakage of blood, interstitial fluid, or cerebrospinal fluid. The formulation may be administered to a burn or ulcer. The formulation may be dispersed in a suture or adhesive for administration at the time of or as released following suturing or gluing of a wound, thereby limiting bleeding, loss of tissue fluids, or other fluids such as those produced by parenchymal tissues such as the liver, pancreas, and gastrointestinal tract.

Abstract: Provided is a current mirror circuit (1) for balancing respective currents in a plurality of parallel circuit branches (2) in a target circuit (3), the current mirror circuit (1) including: a plurality of balancing transistors (4), each having a connector (5), an emitter (6), and a base (7), the collector (5) and emitter (6) of each balancing transistor (4) connected in series with a respective circuit branch (2); a selection circuit (8) that connects the circuit branch (2) having the smallest current amongst the circuit branches (2) to the bases (7) of each balancing transistor; and an isolation circuit (9) that isolates circuit branches (2) having an open circuit fault from the rest of the target circuit (3). An associated method of balancing respective currents in a plurality of parallel circuit branches (2) in a target circuit (3) is also provided.

Abstract: The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity.

Abstract: The present invention provides novel and advantageous materials and methods for preventing and treating viral infection.

Abstract: Described herein are isolated paramyxovirus, a morbillivirus (FmoPV), nucleic acid molecules, polypeptides and antibodies related to FmoPV and uses thereof. In certain embodiments, the FmoPV is a feline morbillivirus. Also described herein is a recombinant FmoPV comprising a modified FmoPV gene or gene segments and uses thereof. Also described is a recombinant FmoPV for the prevention and/or treatment of diseases related to FmoPV or a delivery vector. Also described herein is a diagnostic assay for FmoPV, natural or artificial variants, analogs, or derivatives thereof. Also described herein is a vaccine and a kit containing the vaccine for the prevention and treatment of FmoPV infection. Also provided is a diagnostic kit comprising nucleic acid molecules for the detection of FmoPV.

Abstract: Water-soluble derivatives and/or prodrugs of acacetin are described herein. The compounds can be used as cardioprotection agents against myocardial infarction induced by ischemia-reperfusion. In one embodiment the compounds are used to treat ischemic cardiac diseases. In the preferred embodiment, the compounds are used to treat and/or prevent myocardial infarction in humans.

Abstract: A method is provided to functionally select cells with enhanced characteristics relevant to cell engraftment, including both spontaneous migration and directional migration towards specific chemo-attractants. The cells are preferably undifferentiated cells, such as mesenchymal stem cells. The method involves entrapping or encapsulating the cells in a biomaterial barrier, optionally inducing cell migration, and selecting cells that migrated through the barrier. The cells selected by this method have better migratory activities and enhanced in vivo engraftment to injured tissues when they are supplemented systemically.

Abstract: Compositions which self-assemble under physiological conditions are formulated for application to wounds. The formulations include a pharmaceutically acceptable carrier or are provided as part of a medical device or coating. The formulations may also include other therapeutic, prophylactic or diagnostic agents. The formulation can be administered as appropriate for treatment of one or more disorders or conditions. For example, the formulation may be applied to repair an injury or during surgery of the lung, eye or dura, or following an epidural or spinal tap, to stop leakage of blood, interstitial fluid, or cerebrospinal fluid.

Abstract: The invention provides organometallic complexes comprising an extended ?-conjugated tridentate ligand having a platinum center in which chemical and/or physical properties of the complexes may be modified by changing the structure of the ligands. The complex finds use in devices incorporated into electroluminescent devices, flat panel displays, organic light emitting devices, polymer light emitting devices, transistors, serrors, and lasers.

Abstract: A power compensator for compensating voltage at a location along a power transmission line, the compensator having a controller for controlling a voltage generated across the compensator, wherein the voltage is controlled to maintain a power transmission line voltage at a value dependent on the power transmission line location.

Abstract: An optical transmission system comprises at least one first connection point and one second connection point arranged to transmit and receive at least one channel signal transmitted via at least one optical means connecting the first connection point and the second connection, wherein each of the at least one channel signal is reversibly configurable to be transmitted in either a first direction or a second direction between the first connection point and the second connection point. A method of transmitting at least one channel signal between a first connection point and a second connection point via at least one optical media in an optical transmission system, wherein each of the at least one channel signals is reversibly configurable to be transmitted in either a first direction or a second direction between the first and the second connection points.